372 related articles for article (PubMed ID: 30538305)
1. A banner year for immunotherapy and targeted therapy.
Carlisle JW; Ramalingam SS
Nat Rev Clin Oncol; 2019 Feb; 16(2):79-80. PubMed ID: 30538305
[No Abstract] [Full Text] [Related]
2. Better treatments for lung cancer that spreads to the brain.
Healey N
Nature; 2020 Nov; 587(7834):S14-S15. PubMed ID: 33208971
[No Abstract] [Full Text] [Related]
3. [Immunotherapy for lung cancer].
Ostoros G
Magy Onkol; 2017 Jun; 61(2):153-157. PubMed ID: 28585617
[TBL] [Abstract][Full Text] [Related]
4. There and back again: An immunotherapy tale.
Guo Y; Krupnick AS
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1771-1774. PubMed ID: 29409610
[No Abstract] [Full Text] [Related]
5. Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?
Remon J; Hendriks LE; Cabrera C; Reguart N; Besse B
Cancer Treat Rev; 2018 Dec; 71():47-58. PubMed ID: 30359792
[TBL] [Abstract][Full Text] [Related]
6. KEYNOTE-024: Unlocking a pathway to lung cancer cure?
Rusch VW; Chaft J; Hellmann M
J Thorac Cardiovasc Surg; 2018 Apr; 155(4):1777-1780. PubMed ID: 29395215
[No Abstract] [Full Text] [Related]
7. Reasoning the effect of immunotherapy after chemoradiation in the PACIFIC trial.
Bulbul A; Araujo-Mino E
Future Oncol; 2019 Jan; 15(1):81-94. PubMed ID: 30175621
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Advanced Non-Small Cell Lung Cancer in 2018.
Doroshow DB; Herbst RS
JAMA Oncol; 2018 Apr; 4(4):569-570. PubMed ID: 29494728
[No Abstract] [Full Text] [Related]
9. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
10. Recent progress in systemic treatment for lung cancer.
Clark JW; Longo DL
Curr Opin Pulm Med; 2018 Jul; 24(4):355-366. PubMed ID: 29697418
[TBL] [Abstract][Full Text] [Related]
11. Precision Management of Advanced Non-Small Cell Lung Cancer.
Yang CY; Yang JC; Yang PC
Annu Rev Med; 2020 Jan; 71():117-136. PubMed ID: 31986082
[TBL] [Abstract][Full Text] [Related]
12. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).
Kumarakulasinghe NB; van Zanwijk N; Soo RA
Respirology; 2015 Apr; 20(3):370-8. PubMed ID: 25689095
[TBL] [Abstract][Full Text] [Related]
13. [Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer].
Lupo A; Alifano M; Wislez M; Boulle G; Velut Y; Biton J; Cremer I; Goldwasser F; Leroy K; Damotte D
Rev Pneumol Clin; 2018 Oct; 74(5):339-350. PubMed ID: 30337201
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets.
Smit EF; Baas P
Nat Rev Clin Oncol; 2016 Feb; 13(2):75-6. PubMed ID: 26718109
[No Abstract] [Full Text] [Related]
15. Treatment of older patients with advanced non-small cell lung cancer: A challenge.
Decoster L; Schallier D
J Geriatr Oncol; 2019 Jul; 10(4):528-533. PubMed ID: 30301660
[TBL] [Abstract][Full Text] [Related]
16. Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer.
Dong J; Li B; Zhou Q; Huang D
J Evid Based Med; 2018 Nov; 11(4):278-287. PubMed ID: 30444051
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report.
Kato Y; Watanabe Y; Yamane Y; Mizutani H; Kurimoto F; Sakai H
Immunotherapy; 2020 Apr; 12(6):373-378. PubMed ID: 32314636
[No Abstract] [Full Text] [Related]
18. [Predictive biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer].
Fu MJ; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):87-91. PubMed ID: 32062877
[TBL] [Abstract][Full Text] [Related]
19. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
Hanna N; Johnson D; Temin S; Masters G
J Oncol Pract; 2017 Dec; 13(12):832-837. PubMed ID: 28850309
[No Abstract] [Full Text] [Related]
20. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
